Skip to main content
SpringerLink
Log in

Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

This study was carried out to determine the serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis (AS) and to evaluate its correlation with disease activity and quality of life. According to our knowledge, it is the first trial evaluating HMGB1 levels in AS. Serum samples of 30 patients (18 males and 12 females) with AS and 29 healthy controls (HC) (15 females and 14 males) were collected. HMGB1 levels were measured by enzyme-linked immunosorbent assay, activity of disease was assessed according to the Bath AS Disease Activity Index (BASDAI), and functional status of patients was evaluated with Bath AS Functional Index (BASFI). Modified Schober, chest expansion values and AS Quality of Life Questionnaire (ASQoL) scores were noted. The serum levels of HMGB1 were obtained significantly increased in AS patients compared to HC (p < 0.05). There was no significant correlation between HMGB1 levels and ESR (p > 0.05), and CRP (p > 0.05) values. BASDAI, BASFI and ASQoL scores were also not correlated with serum levels of HMGB1 (p > 0.05). Our results suggest that HMGB1 might play an important role in the pathogenesis of AS; however, it seems not to be a good candidate for reflecting disease activity, functional abilities and the quality of life in patients with AS; on the other hand, the increased levels of HMGB1 in patients may open a new dimension for targeting this cytokine as a new therapy option in AS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gardner DL (1992) Reactive and postinfective arthritis and seronegative spondyloarthropathy. In: Gardner DL (ed) Pathological basis of the connective tissue diseases. London, pp 763–795

  2. Pöllänen R, Sillat T, Pajarinen J et al (2009) Microbial antigens mediate HLA-B27 diseases via TLRs. J Autoimmun 32:172–177

    Article  PubMed  Google Scholar 

  3. Cruickshank B (1956) Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol 71:73–84

    Article  PubMed  CAS  Google Scholar 

  4. Ball J (1971) Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 30:213–223

    Article  PubMed  CAS  Google Scholar 

  5. Sieper J, Appel H, Braun J et al (2008) Critical appraisal of assessment of structural damage in ankylosing spondylitis. Arthritis Rheum 58:649–656

    Article  PubMed  Google Scholar 

  6. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1–5

    Article  PubMed  CAS  Google Scholar 

  7. Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209

    Article  PubMed  Google Scholar 

  8. Taniguchi N, Kawahara K, Yone K et al (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48:971–981

    Article  PubMed  CAS  Google Scholar 

  9. Chun yun ma C, MaJiao Y, Zhang J et al (2012) Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 32:395–402

    Article  Google Scholar 

  10. Yu M, Wang H, Ding A et al (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174–179

    Article  PubMed  CAS  Google Scholar 

  11. Park JS, Gamboni-Robertson F, He Q et al (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290:917–924

    Article  Google Scholar 

  12. Anderson U, Wang H, Palmblad K et al (2000) High mobility group 1 protein (HMG 1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565–570

    Article  Google Scholar 

  13. Bal A, Unlu E, Bahar G et al (2007) Comparison of serum IL-1, sIL-2R, IL-6 and TNF- alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211–215

    Article  PubMed  CAS  Google Scholar 

  14. Gratacos J, Collado A, Fiella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheum 33:927–931

    Article  CAS  Google Scholar 

  15. Taniguchi N, Yoshida K, Ito T et al (2007) The stage specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol 27:5650–5663

    Article  PubMed  CAS  Google Scholar 

  16. Yang J, Shah R, Robling AG, Templeton E et al (2008) HMGB1 is a bone-active cytokine. J Cell Physiol 214:730–739

    Article  PubMed  CAS  Google Scholar 

  17. Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291

    PubMed  CAS  Google Scholar 

  18. Akkoc Y, Karatepe AG, Akar S et al (2005) A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 25:280–284

    Article  PubMed  Google Scholar 

  19. Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285

    PubMed  CAS  Google Scholar 

  20. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al (2003) Development of ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26

    Article  PubMed  CAS  Google Scholar 

  21. Duruoz T, Doward L, Cerrahoglu L et al (2008) Translation and validation of the Turkish version of the ankylosing spondylitis quality of life (ASQoL) Questionnaire. Abstract Book, EULARl

    Google Scholar 

  22. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342

    Article  PubMed  CAS  Google Scholar 

  23. Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505

    Article  PubMed  CAS  Google Scholar 

  24. Braun J, van den Berg R, Baraliakos X et al (2010) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896–904

    Article  Google Scholar 

  25. Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251

    Article  PubMed  CAS  Google Scholar 

  26. Yang H, Wang H, Tracey KJ (2001) HMG-1 rediscovered as a cytokine. Shock 15:247–253

    Article  PubMed  CAS  Google Scholar 

  27. Andersson U, Erlandsson-Harris H (2004) HMGB1 is a potent trigger of arthritis. J Intern Med 255:344–350

    Article  PubMed  CAS  Google Scholar 

  28. Assassi S, Reveille JD, Arnett FC et al (2011) Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5. J Rheumatol 38:87–98

    Article  PubMed  CAS  Google Scholar 

  29. Ek M, Popovic K, Harris HE et al (2006) Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 54:2289–2294

    Article  PubMed  CAS  Google Scholar 

  30. Ahn JK, Cha HS, Bae EK et al (2011) Extracellular high-mobility group box 1 is increased in patients with Behçet’s disease with intestinal involvement. J Korean Med Sci 26:697–700

    Article  PubMed  Google Scholar 

  31. Liu B, Guo CY, Liu WQ et al (2005) The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis. Zhonghua Nei Ke Za Zhi 44:566–569

    PubMed  Google Scholar 

  32. Yildirim K, Erdal A, Karatay S et al (2004) Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 97:350–353

    Article  PubMed  Google Scholar 

  33. Spoorenberg A, van der Heijde D, de Klerk E et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Dicle University, Diyarbakir, Turkey

    Pelin Oktayoglu, Serda Em, Mehmet Tahtasiz, Mehtap Bozkurt, Demet Ucar, Levent Yazmalar & Kemal Nas

  2. Department of Physical Medicine and Rehabilitation, Universal Hospital, Diyarbakir, Turkey

    İbrahim Yardımeden

  3. Department of Physical Medicine and Rehabilitation, Diyarbakir State Hospital, Diyarbakir, Turkey

    Figen Cevik

  4. Department of Biostatistics, Faculty of Medicine, Dicle University, Diyarbakir, Turkey

    Yusuf Celik

  5. Department of Biochemistry, Faculty of Medicine, Dicle University, Diyarbakir, Turkey

    Nuriye Mete

Authors
  1. Pelin Oktayoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serda Em
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Tahtasiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehtap Bozkurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Demet Ucar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Levent Yazmalar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kemal Nas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. İbrahim Yardımeden
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Figen Cevik
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yusuf Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nuriye Mete
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pelin Oktayoglu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oktayoglu, P., Em, S., Tahtasiz, M. et al. Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Rheumatol Int 33, 1327–1331 (2013). https://doi.org/10.1007/s00296-012-2578-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2578-y

Keywords

Search

Navigation